Knowledge of haemodialysis patients concerning methods of preventing hyperphosphataemia
 
More details
Hide details
1
Faculty of Health Sciences in Katowice, Medical University of Silesia, Katowice, Poland
 
2
Department of Internal Medicine, Autoimmune and Metabolic Diseases, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland
 
3
Department of Internal Medicine and Metabolic Diseases, Faculty of Health Sciences in Katowice, Medical University of Silesia, Katowice, Poland
 
4
Department of Nephrology Nefrolux Dąbrowa Górnicza
 
 
Corresponding author
Anna Maria Janus   

Wydział Nauk o Zdrowiu w Katowicach, Śląski Uniwersytet Medyczny w Katowicach, ul. Medyków 12, 40-752 Katowice
 
 
Ann. Acad. Med. Siles. 2020;74:46-59
 
KEYWORDS
TOPICS
ABSTRACT
Introduction::
TThe beginning of renal replacement therapy is generally connected with changing dietary habits. A positive phosphate balance is a major clinical problem, often observed in haemodialysis patients. The treatment of hyperphosphataemia is based primarily on dietary intervention and the use of phosphate binders – medications which bind phosphorus in the gastrointestinal tract. Properly conducted education of patients with CKD helps to perceive the risks resulting from an improper diet.

Material and methods::
The diagnostic survey method with author's own survey questionnaire was used in the study. The survey contained closed questions concerning the knowledge of dietary recommendations for haemodialysis patients enabling the maintenance of the recommended phosphatemia. Statistical analysis was performed with SAS 9.4 software (SAS Institute Inc., Cary, North Carolina, USA), assuming the statistical significance level p < 0.05. The following tests were applied: chi-squared test/Fisher's exact test, due to the small size of subgroups – the Kruskal-Wallis test for comparison of three groups, and the Mann-Whitney U test to compare the two groups.

Results::
Haemodialysis patients were aware of the need for restrictions on the consumption of products with a high phosphorus content, but had problems choosing those recommended when composing meals. The right set of meats was chosen by 44 patients (36%). Dairy consumption in a moderate amount was declared by 74 people (61%). 46 respon-dents (38%) reduced their egg yolk consumption. Out of the range of available cheeses, 92 respondents (76%) declared the consumption of mainly curd cheese. The right set of bakery products was indicated by 31 patients (26%), and 73 patients (60%) avoided carbonated beverages.

Conclusions::
Patients' knowledge concerning the possibilities of preventing hyperphosphataemia was far from insufficient.

 
REFERENCES (22)
1.
Wyskida K., Klejn D., Sadowski L., Koźmiński P., Ciepał J., Hudziak G., Rotkegel S., Tochowicz S., Rowiński M., Arendt-Królikowska M., Uba A., Chudek J. Czynniki wpływające na złe wyrównanie zaburzeń gospodarki wapniowo-fosforanowej u chorych z przewlekłą chorobą nerek leczonych powtarzanymi hemodializami. Nefrol. Dial. Pol. 2012(2); 16: 75–79.
 
2.
Wajdlich M., Pietrasik P., Jarzębski T., Lewarska I., Olejniczak I., Banasiak M., Lipińska-Ojrzanowska A., Ojrzanowski M., Kurnatowska I., Nowicki M. Współpraca z lekarzem i przestrzeganie zaleceń medycznych przez pacjentów w różnych stadiach przewlekłej choroby nerek Nefrol. Dial. Pol. 2011; 15(1): 33–38.
 
3.
Gutiérrez O.M. Contextual poverty, nutrition and chronic kidney disease. Adv Chronic Kidney Dis. 2015; 22(1): 31–38, doi: 10.1053/j.ackd.2014.05.005.
 
4.
Połubicka K., Kaczkan M., Małgorzewicz S., Król E., Białobrzeska B., Rutkowski B. Ocena wiedzy żywieniowej pacjentów z przewleką chorobą nerek w okresie leczenia zachowawczego Nefrol. Dial. Pol. 2013; 17(2): 56–60.
 
5.
Afrasiabifar A., Karimi Z., Hassani P. Roy’s Adaptation Model-Based Patient Education for Promoting the Adaptation of Hemodialysis Patients Iran Red. Crescent Med. J. 2013; 15(7): 566–572, doi: 10.5812/ircmj.12024.
 
6.
Nowicki M. Leczenie hiperfosfatemii w przewlekłej chorobie nerek. Nefrol. Dial. Pol. 2010: 14(3): 140–144.
 
7.
Zhang C., Wen J., Li Z. Fan J. Efficacy and safety of lanthanum carbonate on chronic kidney disease–mineral and bone disorder in dialysis patients: a systematic review. BMC Nephrol. 2013; 14: 226, doi: 10.1186/1471-2369-14-226.
 
8.
Chudek J., Czerwieńska B. Więcek A. Zaburzenia mineralne i kostne pacjentów z przewlekłą chorobą nerek – patofizjologia i leczenie. Nefrol. Dial. Pol. 2008: 12(1): 47–52.
 
9.
Beto J.A., Schury K.A., Bansal V.K. Strategies to promote adherence to nutritional advice in patients with chronic kidney disease: a narrative review and commentary. Int. J. Nephrol. Renovasc. Dis. 2016; 9: 21–33, doi: 10.2147/IJNRD.S76831.
 
10.
Kalantar-Zadeh K. Patient education for phosphorus management in chronic kidney disease. Patient Prefer Adherence 2013; 7: 379–390, doi: 10.2147/PPA.S43486.
 
11.
Askar A.M. Hyperphosphatemia. The hidden killer in chronic kidney disease. Saudi. Med. J. 2015; 36(1): 13–19, doi: 10.15537/smj.2015.1.9843.
 
12.
Wyskida K., Klejn D., Sadowski L., Koźmiński P., Ciepał J., Hudziak G., Rotkegel S., Tochowicz S., Rowiński M., Arendt-Królikowska M., Uba A., Chudek J. Czynniki wpływające na złe wyrównanie zaburzeń gospodarki fosforanowej u chorych z przewlekłą niewydolnością nerek leczonych powtarzanymi hemodializami. Nefrol. Dial. Pol. 2012; 16(2): 75–79.
 
13.
Szurkowski M. Wpływ zindywidualizowanej edukacji na postępowanie zgodnie z zaleceniami lekarskimi i skuteczność leczenia zaburzeń gospodarki wapniowo-fosforanowej u pacjentów z przewlekłą chorobą nerek w stadium 5 poddawanych przewlekłej dializoterapii. Nefrol. Dial. Pol. 2015; 19(1): 32–39.
 
14.
Pennick M., Poole L., Dennis K., Smyth M. Lanthanum Carbonate Reduces Urine Phosphorus Excretion: Evidence of High-Capacity Phosphate Binding. Ren Fail. 2012; 34(3): 263–270, doi: 10.3109/0886022X.2011.649657.
 
15.
Covic A., Passlick-Deetjen J., Kroczak M., Büschges-Seraphin B., Ghenu A., Ponce P., Marzell B., de Francisco A.L. A comparison of calcium acetate/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a controlled, randomized study. Nephrol. Dial. Transplant. 2013; 28(9): 2383–2392, doi: 10.1093/ndt/gft203.
 
16.
D’Alessandro C., Piccoli G.B., Cupisti A. The “phosphorus pyramid”: a visual tool for dietary phosphate management in dialysis and CKD patients. BMC Nephrol. 2015; 16: 9, doi:10.1186/1471-2369-16-9.
 
17.
Karp H., Ekholm P., Kemi V., Itkonen S., Hirvonen T., Närkki S., Lamberg-Allardt C. Differences among total and in vitro digestible phosphorus content of plant foods and beverages. J. Ren. Nutr. 2012; 22(4): 416–422, doi: 10.1053/j.jrn.2011.04.004.
 
18.
Benini O., D’Alessandro C., Gianfaldoni D., Cupisti A. Extra-phosphate load from food additives in commonly eaten foods: a renal and insidious danger for renal patients. J. Ren. Nutr. 2011; 21(4): 303–308.
 
19.
Kalantar-Zadeh K., Gutekunst L., Mehrotra R., Kovesdy C.P., Bross R., Shinaberger C.S., Noori N., Hirschberg R., Benner D., Nissenson A.R., Kopple J.D. Understanding sources of dietary phosphorus in the treatment of patients with chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2010; 5(3): 519–530, doi: 10.2215/CJN.06080809.
 
20.
Taylor L.M., Kalantar-Zadeh K., Markewich T., Colman S., Benner D., Sim J.J., Kovesdy C.A. Dietary egg whites for phosphorus control in maintenance haemodialysis patients: A pilot study. J. Ren. Care. J. Ren. Care. 2011; 37(1): 16–24, doi: 10.1111/j.1755-6686.2011.00212.x.
 
21.
Sehgal A.R., Sullivan C., Leon J.P., Bialostosky K. A public health approach to addressing hyperphosphatemia among dialysis patients J. Ren. Nutr. 2008; 18(3): 256–261, doi: 10.1053/j.jrn.2007.12.002.
 
22.
Pollock J.B., Jaffery J.B. Knowledge of phosphorus compared with other nutrients in maintenance dialysis patients. J. Ren. Nutr. 2007; 17(5): 323–328, doi: 10.1053/j.jrn.2007.05.009.
 
eISSN:1734-025X
Journals System - logo
Scroll to top